The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Mathers Thomas P. since 2015.
The trader's CIK number is 1639978.
At the time of the last reporting, Mathers Thomas P. was the Chief Executive Officer of Colucid Pharmaceuticals, Inc.. (stock ticker symbol CLCD).
Also see all insider trading activities at Colucid Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2017 | CLCD | 0 | $0 | 1,502 | $52,424 | 3,755 | $0 |
| 2016 | CLCD | 0 | $0 | 20,012 | $420,016 | 67,596 | $0 |
| 2015 | CLCD | 7,500 | $53,272 | 0 | $0 | 180,254 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-01-05 | CLCD | Option Ex | 3,755 | .00 | 0 |
| 2017-01-05 | CLCD | Sale | 1,502 | 34.90 | 52,424 |
| 2016-11-07 | CLCD | Sale | 1,502 | 28.57 | 42,916 |
| 2016-11-05 | CLCD | Option Ex | 3,755 | .00 | 0 |
| 2016-10-05 | CLCD | Option Ex | 3,755 | .00 | 0 |
| 2016-10-05 | CLCD | Sale | 1,502 | 37.08 | 55,694 |
| 2016-09-14 | CLCD | Sale | 6,000 | 23.54 | 141,240 |
| 2016-09-07 | CLCD | Sale | 5,000 | 22.58 | 112,899 |
| 2016-09-05 | CLCD | Option Ex | 3,756 | .00 | 0 |
| 2016-09-06 | CLCD | Sale | 1,502 | 19.50 | 29,289 |
| 2016-08-05 | CLCD | Option Ex | 3,755 | .00 | 0 |
| 2016-08-05 | CLCD | Sale | 1,502 | 8.31 | 12,481 |
| 2016-07-05 | CLCD | Option Ex | 3,755 | .00 | 0 |
| 2016-07-05 | CLCD | Sale | 1,502 | 9.73 | 14,614 |
| 2016-06-06 | CLCD | Sale | 1,502 | 7.25 | 10,883 |
| 2016-06-05 | CLCD | Option Ex | 3,756 | .00 | 0 |
| 2016-05-05 | CLCD | Option Ex | 45,064 | .00 | 0 |
| 2015-11-05 | CLCD | Option Ex | 180,254 | .00 | 0 |
| 2015-08-25 | CLCD | Buy | 7,500 | 7.10 | 53,272 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Mathers Thomas P. (Chief Executive Officer of Colucid Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.